Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California San Diego, discusses the PDIGREE study design for the treatment of renal cell carcinoma (RCC). Patients initially receive nivolumab plus ipilimumab. Those patients who exhibit a complete response continue on nivolumab maintenance, while patients with progressive disease are switched to cabozantinib. Patients without complete response or progressive disease are then randomized to receive either nivolumab plus cabozantinib or nivolumab alone.
Learn more by clicking here.